The pharmaceutical The industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the severity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapy and artificial intelligence (AI). In the past three years alone, more than 633,000 patents have been filed and granted in the pharmaceutical industry, according to GlobalData’s report on Artificial Intelligence in Pharmaceuticals: DNA Polymorphism Detection.
However, not all innovations are created equal, nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that mirrors their typical life cycle, from early emergence to accelerated adoption before finally leveling off and reaching maturity.
Identifying where a particular innovation is on this journey, especially those in the emerging and accelerating phases, is critical to understanding their current level of adoption and the likely future trajectory and impact that ‘they will have.
110 innovations will shape pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models based on more than 756,000 patents, there are 110 areas of innovation that will shape the future of the industry. ‘industry.
Within the emerging the innovation phase for AI, microarrays, tissue culture automation and mass spectrometry analysis are examples of disruptive technologies that are in the early stages of application and need to be followed by close. DNA binding site prediction, peptide structure optimization and AI-assisted genome analysis are accelerating areas of innovation for AI in the pharmaceutical industry, where adoption has been steadily increasing. Among maturation areas of innovation are in silico drug discovery, DNA polymorphism detection and genome sequence analysis, which are now well established in the industry.
S-curve of innovation for artificial intelligence in the pharmaceutical industry
DNA polymorphism detection is a key area of innovation in artificial intelligence
Studying human genetic variation has led to a better understanding of common and rare diseases, accelerating the pace of drug development, and paving the way for the future of precision medicine. Exploring genotyping analysis uncovers the complex relationships between genotype and phenotype and attempts to focus on single nucleotide polymorphisms (SNPs), insertion or deletion polymorphisms (indels), and copy number variants (CNV).
GlobalData’s analysis also reveals which companies are at the forefront of each area of innovation and assesses the potential reach and impact of their patenting activity in different applications and geographies. According to GlobalData, more than 80 companies, spanning technology providers, established pharmaceutical companies and emerging start-ups, are engaged in the development and application of DNA polymorphism detection.
Key players in DNA polymorphism detection – a breakthrough innovation in the pharmaceutical industry
“Application diversity” measures the number of different applications identified for each relevant patent and broadly divides companies into “niche” or “diversified” innovators.
“Geographical scope” refers to the number of different countries in which each relevant patent is registered and reflects the scope of intended geographical application, ranging from “global” to “local”.
Thermo Fisher Scientific is one of the innovators in the field of genotyping. It offers a comprehensive portfolio of genotyping solutions for SNP, indel and CNV analysis. It also provides solutions such as genotyping arrays, real-time polymerase reaction (PCR) for genotyping, targeted genotyping by sequencing, digital PCR for genotyping, fragment analysis by capillary electrophoresis and in situ hybridization.
In terms of diversity of applications, Axcella Health is the leading company, followed by Pronutria Biosciences and Curevac. In terms of geographic reach, Baxter International ranks first. TRON and the Center for Addiction and Mental Health occupy the second and third positions respectively.
To better understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest topical research report on Artificial Intelligence (AI) in Healthcare – Topic Research.
#Innovation #Artificial #Intelligence #Leading #companies #detection #DNA #polymorphisms #pharmaceutical #industry